Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Victoria L Bae-Jump

Showing results (91-100 of 100) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 100 results.
Plos One|January 23, 2026
Stool and vaginal microbiome profiles patterns among Black and White endometrial cancer survivors: A pilot study in North CarolinaMu Jin, Temitope Keku, Amber McCoy, et al.
Gynecologic Oncology|April 26, 2024
Intermittent energy restriction inhibits tumor growth and enhances paclitaxel response in a transgenic mouse model of endometrial cancerZiyi Zhao, Jiandong Wang, Weimin Kong, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 18, 2013
Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacologyWhitney P Caron, John C Lay, Alan M Fong, et al.
Oncotarget|November 16, 2017
Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trialsHelen J MacKay, Douglas A Levine, Victoria L Bae-Jump, et al.
Oncotarget|October 4, 2017
Dual inhibition of glycolysis and glutaminolysis as a therapeutic strategy in the treatment of ovarian cancerLi Sun, Yajie Yin, Leslie H Clark, et al.
Biorxiv : the Preprint Server for Biology|January 7, 2025
PAX2 is Transcriptionally Silenced by a Distinct Mechanism of Epigenetic Reprogramming to Initiate Endometrial CarcinogenesisSubhransu S Sahoo, Susmita G Ramanand, Ileana C Cuevas, et al.
The Journal of Clinical Investigation|August 19, 2025
A distinct mechanism of epigenetic reprogramming silences PAX2 and initiates endometrial carcinogenesisSubhransu S Sahoo, Susmita G Ramanand, Ileana C Cuevas, et al.
Gynecologic Oncology|March 8, 2025
A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG studyVictoria L Bae-Jump, Michael W Sill, Paola A Gehrig, et al.
Plos One|April 2, 2015
Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriersIgnacio Blanco, Karoline Kuchenbaecker, Daniel Cuadras, et al.
Plos Genetics|April 2, 2013
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer riskFergus J Couch, Xianshu Wang, Lesley McGuffog, et al.
Pageof 10

Showing results (91-100 of 100) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 100 results.
Plos One|January 23, 2026
Stool and vaginal microbiome profiles patterns among Black and White endometrial cancer survivors: A pilot study in North CarolinaMu Jin, Temitope Keku, Amber McCoy, et al.
Gynecologic Oncology|April 26, 2024
Intermittent energy restriction inhibits tumor growth and enhances paclitaxel response in a transgenic mouse model of endometrial cancerZiyi Zhao, Jiandong Wang, Weimin Kong, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 18, 2013
Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacologyWhitney P Caron, John C Lay, Alan M Fong, et al.
Oncotarget|November 16, 2017
Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trialsHelen J MacKay, Douglas A Levine, Victoria L Bae-Jump, et al.
Oncotarget|October 4, 2017
Dual inhibition of glycolysis and glutaminolysis as a therapeutic strategy in the treatment of ovarian cancerLi Sun, Yajie Yin, Leslie H Clark, et al.
Biorxiv : the Preprint Server for Biology|January 7, 2025
PAX2 is Transcriptionally Silenced by a Distinct Mechanism of Epigenetic Reprogramming to Initiate Endometrial CarcinogenesisSubhransu S Sahoo, Susmita G Ramanand, Ileana C Cuevas, et al.
The Journal of Clinical Investigation|August 19, 2025
A distinct mechanism of epigenetic reprogramming silences PAX2 and initiates endometrial carcinogenesisSubhransu S Sahoo, Susmita G Ramanand, Ileana C Cuevas, et al.
Gynecologic Oncology|March 8, 2025
A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG studyVictoria L Bae-Jump, Michael W Sill, Paola A Gehrig, et al.
Plos One|April 2, 2015
Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriersIgnacio Blanco, Karoline Kuchenbaecker, Daniel Cuadras, et al.
Plos Genetics|April 2, 2013
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer riskFergus J Couch, Xianshu Wang, Lesley McGuffog, et al.
Pageof 10